Corvus Pharmaceuticals (CRVS) Leases (2022 - 2025)
Corvus Pharmaceuticals (CRVS) has 4 years of Leases data on record, last reported at $927000.0 in Q3 2025.
- For Q3 2025, Leases rose 226.41% year-over-year to $927000.0; the TTM value through Sep 2025 reached $927000.0, up 226.41%, while the annual FY2024 figure was $1.2 million, 2.44% up from the prior year.
- Leases reached $927000.0 in Q3 2025 per CRVS's latest filing, down from $1.0 million in the prior quarter.
- Across five years, Leases topped out at $3.0 million in Q1 2022 and bottomed at $284000.0 in Q3 2024.
- Average Leases over 4 years is $1.5 million, with a median of $1.2 million recorded in 2024.
- Peak YoY movement for Leases: tumbled 80.04% in 2024, then skyrocketed 226.41% in 2025.
- A 4-year view of Leases shows it stood at $2.2 million in 2022, then plummeted by 48.17% to $1.1 million in 2023, then grew by 2.44% to $1.2 million in 2024, then fell by 21.24% to $927000.0 in 2025.
- Per Business Quant database, its latest 3 readings for Leases were $927000.0 in Q3 2025, $1.0 million in Q2 2025, and $1.1 million in Q1 2025.